Study of Probuphine in Patients With Opioid Dependence (PRO-809)

This study has been terminated.
(This study was terminated for reasons not related to efficacy or safety)
Sponsor:
Information provided by (Responsible Party):
Titan Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00772785
First received: October 9, 2008
Last updated: January 25, 2013
Last verified: October 2012
  Purpose

Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine (buprenorphine implant) is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patients with opioid dependence. Patients who have completed at least 24 weeks of treatment in the Open-Label, Multi-Center Study of Probuphine in Patients with Opioid Dependence (PRO-807 Study), will be re-treated with Probuphine over an additional 24 weeks.


Condition Intervention Phase
Opioid Dependency
Drug: Probuphine (buprenorphine implant)
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Multi-center Extension Study of Probuphine in Patients With Opioid Dependence

Resource links provided by NLM:


Further study details as provided by Titan Pharmaceuticals:

Primary Outcome Measures:
  • Number of adverse events [ Time Frame: 24 WEEKS ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Plasma buprenorphine concentration [ Time Frame: 24 WEEKS ] [ Designated as safety issue: No ]

Enrollment: 16
Study Start Date: September 2008
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Probuphine
buprenorphine implant
Drug: Probuphine (buprenorphine implant)
Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants 6-month duration)

Detailed Description:

This is a 6-month, open-label, multi-center extension study. It is estimated that approximately 200 patients will be enrolled at approximately 25 sites in the United States (US). Following completion of either the PRO-807(NCT00630201) or PRO-808 studies, eligible patients will be implanted with Probuphine implants in the opposite arm for the PRO-809 study. Safety, BPN plasma levels, and efficacy measures will be collected during the 24-week treatment period.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients must meet the following eligibility criteria:

  • Expected to complete 24 weeks of treatment in PRO-807 or PRO-808
  • Voluntarily provide written informed consent prior to the conduct of any study-related procedures
  • Deemed appropriate for entry into this re-treatment study by the Investigator
  • Females of childbearing potential and fertile males must use a reliable means of contraception

Exclusion Criteria:

Patients are not eligible for enrollment if any of the following criteria are met:

  • Presence of aspartate aminotransferase (AST) levels ≥ 3 X upper limit of normal and/or alanine aminotransferase (ALT) levels ≥ 3 X upper limit of normal and/or total bilirubin ≥ 1.5 X upper limit of normal and/or creatinine ≥ 1.5 X upper limit of normal, measured at the time of the Week 20 Visit for the previous trial (PRO-807 or PRO-808), or any time less than 5 weeks prior to the Implant Visit.
  • Current diagnosis of chronic pain requiring opioids for treatment
  • Pregnant or lactating females
  • Current use of agents metabolized through cytochrome P450 3A4 (CYP 3A4) such as azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), and protease inhibitors (e.g., ritonavir, indinavir, and saquinavir)
  • Current history of coagulopathy and anti-coagulant therapy (such as warfarin)
  • Current use of benzodiazepines other than physician prescribed use
  • Significant medical or psychiatric symptoms, cognitive impairment, or other factors which in the opinion of the Investigator, would preclude compliance with the protocol, patient safety, adequate cooperation in the study, or obtaining informed consent
  • Concurrent medical conditions (such as severe respiratory insufficiency) that may prevent the patient from safely participating in study; and/or any pending legal action that could prohibit participation and/or compliance in the study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00772785

Locations
United States, Florida
Scientific Clinical Research, Inc.
North Miami, Florida, United States, 33161
Sponsors and Collaborators
Titan Pharmaceuticals
  More Information

No publications provided

Responsible Party: Titan Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00772785     History of Changes
Other Study ID Numbers: PRO-809
Study First Received: October 9, 2008
Last Updated: January 25, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Titan Pharmaceuticals:
opioid dependence
opioid addiction
buprenorphine
methadone
heroin
implant
opioid withdrawal
opioid pain medication
suboxone

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Mental Disorders
Buprenorphine
Analgesics, Opioid
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Central Nervous System Depressants
Narcotic Antagonists
Narcotics

ClinicalTrials.gov processed this record on April 17, 2014